Literature DB >> 17960335

Risk of second malignancies after prostate irradiation?

Arndt-Christian Müller1, Ute Ganswindt, Michael Bamberg, Claus Belka.   

Abstract

PURPOSE: Several recent SEER- (Surveillance, Epidemiology and End Results-) analyses gave rise to a highly controversial discussion in how far radiotherapy for prostate cancer is associated with an increased risk of secondary neoplasms.
MATERIAL AND METHODS: In order to enable a rational discussion, the available literature was reviewed covering all publications from the mid 80s to January 2007.
RESULTS: The reported numbers of secondary cancer (bladder, rectum, lung cancer and sarcoma) after irradiation were found to be increased in some publications. However, after age adjustment and correction for follow-up duration no clear increase was detectable. DISCUSSION: Up to now, all available data are highly heterogeneous. Thus, a low risk for secondary cancer cannot be ruled out completely. Nevertheless, it seems very unlikely that there is a relevant risk for secondary cancer since the largest of the published series did not document an increased risk for any secondary cancer.
CONCLUSION: Only very large prospective studies which are designed to minimize the influence of possible confounders will be able to address the real risk of prostate irradiation-related cancer induction. The available data are clearly not valid and helpful for guiding any treatment decision.

Entities:  

Mesh:

Year:  2007        PMID: 17960335     DOI: 10.1007/s00066-007-1786-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  16 in total

1.  Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer.

Authors:  Tracy L Klayton; Karen Ruth; Eric M Horwitz; Robert G Uzzo; Alexander Kutikov; David Y T Chen; Mark Sobczak; Mark K Buyyounouski
Journal:  Radiother Oncol       Date:  2011-08-31       Impact factor: 6.280

2.  Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.

Authors:  Amy Berrington de Gonzalez; Jeannette Wong; Ruth Kleinerman; Clara Kim; Lindsay Morton; Justin E Bekelman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-02-01       Impact factor: 7.038

3.  Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer : prognostic significance of tumor regression.

Authors:  Hans Theodor Eich; Anna Stepien; Christian Zimmermann; Martin Hellmich; Ralf Metzger; Arnulf Hölscher; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2011-03-07       Impact factor: 3.621

4.  Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers.

Authors:  Phillip J Taddei; Nabil Khater; Bassem Youssef; Rebecca M Howell; Wassim Jalbout; Rui Zhang; Fady B Geara; Annelise Giebeler; Anita Mahajan; Dragan Mirkovic; Wayne D Newhauser
Journal:  Biomed Phys Eng Express       Date:  2018-02-07

5.  Bladder cancer in cancer patients: population-based estimates from a large Swedish study.

Authors:  J Lorenzo Bermejo; J Sundquist; K Hemminki
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

6.  Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion.

Authors:  Michael Pinkawa; Martin Pursch-Lee; Branka Asadpour; Bernd Gagel; Marc D Piroth; Jens Klotz; Sandra Nussen; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2008-12-24       Impact factor: 3.621

7.  What is the value of routine follow-up in stage I seminoma after paraaortic radiotherapy?: an analysis of the German Testicular Cancer Study Group (GTCSG) in 675 prospectively followed patients.

Authors:  Johannes Clasen; Heinz Schmidberger; Rainer Souchon; Lothar Weissbach; Michael Hartmann; Jörg T Hartmann; Thomas Hehr; Michael Bamberg
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

8.  Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis.

Authors:  Michael Pinkawa; Marc D Piroth; Branka Asadpour; Bernd Gagel; Karin Fischedick; Jaroslav Siluschek; Mareike Kehl; Barbara Krenkel; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2009-02-25       Impact factor: 3.621

Review 9.  Prostate angiosarcoma: is there any association with previous radiation therapy?

Authors:  Waseem Khaliq; Christian F Meyer; Ikechukwu Uzoaru; Richard M Wolf; Emmanuel S Antonarakis
Journal:  BJU Int       Date:  2012-05-15       Impact factor: 5.588

Review 10.  The pathology of urinary bladder lesions with an inverted growth pattern.

Authors:  Aitao Guo; Aijun Liu; Xiaodong Teng
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.